Novo real-world data link semaglutide 2 mg dose escalation to 6% lower cardiovascular risk
A separate observational study with telehealth platform Ro tracked 194 patients switching from injectables to oral Wegovy, with 4.1% average weight loss over three months.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 2 14:31 ETSource: AD HOC NEWS
The wire
- 01A claims analysis of 636,525 adults with type 2 diabetes found escalating to semaglutide 2 mg was associated with a statistically significant 6% lower risk of major cardiovascular events than switching to tirzepatide.
- 02Prescribers weighing dose escalation against a switch to tirzepatide now have comparative real-world signal, and the OCTANE data give operators a first look at injectable-to-oral transitions.
- 03Both analyses are observational, without randomization or control groups; Novo says safety endpoints were out of scope, and OCTANE omitted side effects and prior injectable doses.
From the source
Read at ad-hoc-news.deNovo Nordisk's Semaglutide Edges Out Tirzepatide on Heart Risk as Oral Wegovy Sheds Pounds in Real-W
Novo Nordisk has rolled out two separate sets of data that bolster the case for its semaglutide franchise, even as the Danish drugmaker's shares continue to languish near their lowest levels of the year. The findings — one comparing semaglutide head-to-head against a rival therapy, the other tracking patients who switched from injections to a daily pill — landed during a stretch in which investors
